You are here

Targeting Latexin for radiation mitigation.

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43AI145726-01
Agency Tracking Number: R43AI145726
Amount: $581,320.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIAID
Solicitation Number: PA18-525
Timeline
Solicitation Year: 2018
Award Year: 2019
Award Start Date (Proposal Award Date): 2019-05-06
Award End Date (Contract End Date): 2021-04-30
Small Business Information
3130 HIGHLAND AVE UNIT 2
Cincinnati, OH 45219-2399
United States
DUNS: 182472162
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 SOMASUNDAR GABBITA
 (513) 475-6618
 pgabbita@p2dinc.com
Business Contact
 RENEE OCONNOR
Phone: (513) 475-6618
Email: rmoconnor@p2dinc.com
Research Institution
N/A
Abstract

The purpose of this grant is to develop novel therapeutic approaches for
radiological/nuclear medical countermeasures. Very few medical products have been
shown to counter the acute and long-term injuries that can result from a nuclear or
radiological accident or attack. Medical products and regimens that mitigate and/or treat
radiation injury post-exposure (i.e., administration of first dose to start at least 24 hours
after radiation exposure), with emphasis on ease of administration in a mass casualty
and emergency scenario; safety; and long shelf-life are still to be developed and are thus
of high priority. Therapeutic administration of a drug that inhibits the activity of the
protein latexin in hematopoietic stem cells (HSCs) resulted in mitigation of HSC function.
These findings suggest that pharmacologic augmentation of the activity of such a drug,
in combination with additional mitigators currently developed, might offer a rational
approach to the mitigation of tissue injury and lethality caused by ionizing radiation that
especially affects hematopoiesis.Very few medical products have been shown to counter the acute and long-term injuries
that can result from a nuclear or radiological accident or attack. Recent non-terrorist
related accidents have also increased global and national attention to the need for medical
countermeasures. This proposal seeks to test whether a chemical compound that targets
a specific protein and that shows radio-mitigation for hematopoietic stem cells might be
further developed into a full radiation mitigation compound and ultimately a drug.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government